238 related articles for article (PubMed ID: 15361245)
1. The immunopathology of experimental visceral leishmaniasis.
Kaye PM; Svensson M; Ato M; Maroof A; Polley R; Stager S; Zubairi S; Engwerda CR
Immunol Rev; 2004 Oct; 201():239-53. PubMed ID: 15361245
[TBL] [Abstract][Full Text] [Related]
2. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis.
Engwerda CR; Ato M; Kaye PM
Trends Parasitol; 2004 Nov; 20(11):524-30. PubMed ID: 15471704
[TBL] [Abstract][Full Text] [Related]
3. Immunohistological features of visceral leishmaniasis in BALB/c mice.
Carrión J; Nieto A; Iborra S; Iniesta V; Soto M; Folgueira C; Abanades DR; Requena JM; Alonso C
Parasite Immunol; 2006 May; 28(5):173-83. PubMed ID: 16629702
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice.
Bradley DJ; Kirkley J
Clin Exp Immunol; 1977 Oct; 30(1):119-29. PubMed ID: 606433
[TBL] [Abstract][Full Text] [Related]
5. [Experimental visceral leishmaniasis in golden hamsters].
Shukina EE; Gorbunova LA
Parazitologiia; 1987; 21(5):637-42. PubMed ID: 3431905
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-10 and the pathogenesis of human visceral leishmaniasis.
Nylén S; Sacks D
Trends Immunol; 2007 Sep; 28(9):378-84. PubMed ID: 17689290
[TBL] [Abstract][Full Text] [Related]
7. Lack of CXCR3 delays the development of hepatic inflammation but does not impair resistance to Leishmania donovani.
Barbi J; Oghumu S; Rosas LE; Carlson T; Lu B; Gerard C; Lezama-Davila CM; Satoskar AR
J Infect Dis; 2007 Jun; 195(11):1713-7. PubMed ID: 17471442
[TBL] [Abstract][Full Text] [Related]
8. Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection.
Melby PC; Tabares A; Restrepo BI; Cardona AE; McGuff HS; Teale JM
Exp Parasitol; 2001 Sep; 99(1):17-25. PubMed ID: 11708830
[TBL] [Abstract][Full Text] [Related]
9. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
10. The role of mannose receptor during experimental leishmaniasis.
Akilov OE; Kasuboski RE; Carter CR; McDowell MA
J Leukoc Biol; 2007 May; 81(5):1188-96. PubMed ID: 17261547
[TBL] [Abstract][Full Text] [Related]
11. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
12. Involvement of CD4⁺ Foxp3⁺ regulatory T cells in persistence of Leishmania donovani in the liver of alymphoplastic aly/aly mice.
Tiwananthagorn S; Iwabuchi K; Ato M; Sakurai T; Kato H; Katakura K
PLoS Negl Trop Dis; 2012; 6(8):e1798. PubMed ID: 22928057
[TBL] [Abstract][Full Text] [Related]
13. Leishmania donovani: clinical, hematologic and hepatic changes in squirrel monkeys (Saimiri sciureus).
Dennis VA; Chapman WL; Hanson WL; Lujan R
J Parasitol; 1985 Oct; 71(5):576-82. PubMed ID: 4057001
[TBL] [Abstract][Full Text] [Related]
14. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
15. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
16. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
18. A novel approach to regulate experimental visceral leishmaniasis in murine macrophages using CCR5 siRNA.
Bhattacharyya S; Dey R; Majumder N; Bhattacharjee S; Majumdar S
Scand J Immunol; 2008 Apr; 67(4):345-53. PubMed ID: 18282231
[TBL] [Abstract][Full Text] [Related]
19. Leishmania infantum-induced primary and challenge infections in rhesus monkeys (Macaca mulatta): a primate model for visceral leishmaniasis.
Porrozzi R; Pereira MS; Teva A; Volpini AC; Pinto MA; Marchevsky RS; Barbosa AA; Grimaldi G
Trans R Soc Trop Med Hyg; 2006 Oct; 100(10):926-37. PubMed ID: 16455120
[TBL] [Abstract][Full Text] [Related]
20. Balancing immunity and pathology in visceral leishmaniasis.
Stanley AC; Engwerda CR
Immunol Cell Biol; 2007; 85(2):138-47. PubMed ID: 17146466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
